SEC Form 4 · accession 0001609284-26-000003
OnKure Therapeutics, Inc. · OKUR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Nicholas A Saccomano
Officer — President and CEO · Director
Period of report
Jun 22, 2026
Accepted (ET)
Jun 24, 2026 · 7:29 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001637715
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Class A Common StockF2,F3,F4 | Jun 22, 2026 | S | 86 | $4.3963 | D | 11,247 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1These shares were automatically sold to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"), pursuant to the terms of the Issuer's 2023 RSU Equity Incentive Plan.
- F2This transaction was executed in multiple trades at prices ranging from $4.27 to $4.54. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- F3Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Class A Common Stock, subject to the applicable vesting schedule and conditions of each RSU.
- F4Includes 4,000 shares acquired under the Issuer's 2024 Employee Stock Purchase Plan on May 20, 2026.